Apple Watch-Guided Anticoagulation After Atrial Fibrillation Ablation　― The Up to AF Trial ―

20260 citationsJournal Articlediamond Open Access

Authors

A Sunaga · The University of Osaka

Nobuaki Tanaka

Yasuyuki Egami · Osaka Rosai Hospital

H Minamiguchi · Osaka Police Hospital

Masato Kawasaki · Osaka Prefectural Medical Center

Takafumi Oka · The University of Osaka

Koichi Inoue · Osaka National Hospital

Abstract

In this cohort, Apple Watch-guided event-triggered anticoagulation markedly reduced DOAC exposure without thromboembolic events. Given the limited sample size and low baseline thromboembolic risk, these safety findings should be interpreted cautiously. Results were similar in the prespecified analysis restricted to patients with CHA<sub>2</sub>DS<sub>2</sub>-VASc scores of 2-3, the group for whom postablation anticoagulation decisions are most clinically relevant.

Topics & Keywords

Atrial Fibrillation Management and Outcomes Venous Thromboembolism Diagnosis and Management Heparin-Induced Thrombocytopenia and Thrombosis

Publication Details

Published in: Circulation Journal

DOI: 10.1253/circj.cj-26-0066

Field-Weighted Citation Impact: 0.00

Command Palette

Apple Watch-Guided Anticoagulation After Atrial Fibrillation Ablation ― The Up to AF Trial ―

Authors

Abstract

Topics & Keywords

Publication Details

Apple Watch-Guided Anticoagulation After Atrial Fibrillation Ablation　― The Up to AF Trial ―